2023
DOI: 10.1016/j.xphs.2022.11.001
|View full text |Cite
|
Sign up to set email alerts
|

The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
37
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 75 publications
(50 citation statements)
references
References 122 publications
0
37
0
Order By: Relevance
“…Beyond the acidic milieu, the other likely contributing factor to LNP disintegration is the limited stability of the vaccine in water, as reflected in the brief (up to 6h) shelf-life of Comirnaty on RT after dilution. 42–44…”
Section: Resultsmentioning
confidence: 99%
See 3 more Smart Citations
“…Beyond the acidic milieu, the other likely contributing factor to LNP disintegration is the limited stability of the vaccine in water, as reflected in the brief (up to 6h) shelf-life of Comirnaty on RT after dilution. 42–44…”
Section: Resultsmentioning
confidence: 99%
“…These NPs are "softer" than the standard bilayer liposomes or other LNPs with fuller membrane coverage, which may explain the diluted vaccine's limited stability on ambient temperature. [42][43][44] Despite its softness, and, hence, limited stability, the vaccine is clearly very effective in inducing an immune response, raising the possibility that the above newly recognized structural features are contributing to, or may be essential for its immunogenic function. Our data may therefore lay the grounds for a paradigm shift in understanding the structure-function relationship in mRNA vaccines, as well as contribute to developing better imaging of LNP core structure.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…alternative poly(A) tail designs 13 ) or the potential introduction of hidden open reading frames within the gene of interest or during construct design and optimization 28 . In the formulated vaccine drug product, the lipid nanoparticle protects the mRNA from hydrolytic fragmentation; however, additional mRNA degradation mechanisms (e.g., through interactions with lipid excipients in the formulated drug product 29 , 30 ) can potentially affect antigen translation. While not in scope of the present study, these non-hydrolytic degradation mechanisms should be explored and appropriately controlled in the final drug product.…”
Section: Discussionmentioning
confidence: 99%